Zydus Lifesciences Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Zydus Lifesciences Limited generated cash of $26,402,000,000, which is less than the previous year. Cash used in financing activities reached the amount of -$42,742,000,000 last year. Net change in cash is therefore -$6,143,000,000.
Cash Flow
| 2010 | 6.32B | -3.81B | -2.51B |
|---|---|---|---|
| 2011 | 6.69B | -4.53B | -1.72B |
| 2012 | 5.01B | -11.90B | 8.59B |
| 2016 | 19.93B | -9.03B | -9.52B |
| 2018 | 9.19B | -9.73B | 515M |
| 2020 | 26.5B | -10.45B | -12.05B |
| 2021 | 31.58B | -7.73B | -23.63B |
| 2023 | 26.40B | 10.93B | -42.74B |
CADILAHC.NS Cash Flow Statement (2010 – 2022)
| 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 11.06B | 9.64B | 6.49B | 15.92B | 7.90B | 2.95B | 2.50B | 2.51B |
Operating activities | ||||||||
Net income | 19.64B | 22.01B | 11.76B | 17.75B | 15.22B | 6.52B | 7.11B | 5.05B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 7.22B | 6.69B | 6.96B | 5.40B | 3.02B | 1.57B | 1.26B | 1.33B |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -8.48B | 4.31B | 2.82B | 0 | 0 | 0 | 0 | 0 |
Inventories | 4.40B | -4.79B | -1.01B | -5.92B | 845M | -2.78B | -615M | -1.49B |
Accounts payable | -1.70B | 1.70B | 564M | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 26.40B | 31.58B | 26.5B | 9.19B | 19.93B | 5.01B | 6.69B | 6.32B |
Investing activities | ||||||||
Purchases Of Investments | -2.60B | -400M | -1.85B | 0 | -1M | -1.66B | -5M | -842M |
Investments In Property Plant And Equipment | -10.30B | -8.54B | -9.04B | -10.49B | -9.71B | -12.44B | -4.89B | -3.32B |
Acquisitions Net | 794M | 1.10B | -1.69B | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 10.93B | -7.73B | -10.45B | -9.73B | -9.03B | -11.90B | -4.53B | -3.81B |
Financing activities | ||||||||
Common Stock Issued | 0 | 9.86B | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | -2.67B | -15M | -8.56B | 0 | -5.78B | -1.26B | -1.01B | -154M |
Repurchases of common stock | -8.63B | 9.59B | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -33.42B | 0 | 0 | 0 | -2.90B | -601M | -1.76B |
Cash used in financing activities | -42.74B | -23.63B | -12.05B | 515M | -9.52B | 8.59B | -1.72B | -2.51B |
Net Change In Cash | -6.14B | -766M | 3.15B | -29M | 1.37B | 1.71B | 445M | -10M |
Cash at end of period | 4.92B | 8.88B | 9.64B | 15.89B | 9.27B | 4.66B | 2.95B | 2.50B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |